Long-Term Thesis

Long-Term Thesis — What Has To Be True Over the Next 5–10 Years

1. Long-Term Thesis in One Page

The long-term thesis is that Yadea spends the next decade as the cash-generative scale incumbent of a structurally consolidating Chinese consumer-durables oligopoly that is being slowly, partially exported into Southeast Asia — and that the controlling family chooses to surface the ¥17B cash pile rather than hoard it indefinitely. This is not a long-duration compounder unless three things happen together over five-to-ten years: (a) the post-2024 Standard Conditions and lithium-safety rules drive the ~80 small private OEMs out, lifting top-five share from ~50% toward 60%+ and giving Yadea durable mid-cycle gross margins in the 16–18% band; (b) Vietnam, Indonesia, and broader Southeast Asia replicate the China dealer playbook well enough to move international revenue mix from ~5% toward 15–20% by FY2030; and (c) the Dong/Qian family converts the cash pile from a stranded asset into a sustained 50%+ payout-ratio regime, with periodic specials or a real buyback authorization. If those three converge, the operating business compounds at 8–10% revenue with ~22% normalized ROE on operating equity, and the cash returns close the AIMA-to-Yadea multiple gap. If they don't, this is a cyclical OEM at a fair multiple with a permanently-discounted cash hoard — a 7% total-return name, not a compounder.

2. The 5-to-10-Year Underwriting Map

A small number of durable drivers carry the multi-year case. Each must be observable and each must have both a validation and a refutation signal. Cycle-print details, near-term inventory swings, and quarter-to-quarter ASP wiggle live in the technicals and short-interest pages; this table is the long-duration scoreboard.

The driver that matters most is capital-return regime change. The other five drivers determine the operating-business multiple, but the cash pile is what currently makes the headline P/E misleading: at the FY2025 print, ~58% of market cap was inert net cash earning roughly 2%. Until a credible, repeatable payout-ratio floor or buyback program emerges, the operating business will trade at AIMA-discount levels, the multiple gap won't close, and the durable consolidation thesis will be expressed mostly as dividend yield, not as a re-rating. If the family chooses to compound the cash inside the trust forever, the long-term thesis becomes simply a ~7% dividend yield with optionality — fine, but not a compounder. The single largest 5-year delta is whether the FY2025 special was the start of a regime or a one-off sweetener.

3. Compounding Path

Yadea's compounding math is unusual because the operating business is a 22-27% ROE franchise sitting on top of a balance sheet that holds half its assets in cash and treasury investments. The right way to read multi-year compounding is to separate (i) operating-business growth + margin + cash conversion from (ii) cash-pile policy. Both have to work for the equity to compound at the rates the cash, ROE, and market position suggest are achievable.

The history shows a 7-year revenue CAGR of ~17.5% (¥11.97B → ¥37.01B) and a ~28% NI CAGR but with an FY2024 trough that cut earnings in half. The right way to underwrite the next 5–10 years is to discount the cyclical extremes and ask what the through-cycle picture supports. The table below frames a base case for FY2030 with the assumptions made explicit; this is a thesis-scoping exercise, not a forecast.

The compounding map sums to a base-case 8–14% IRR over a five-year window — a decent, not spectacular, return — with the dispersion concentrated in two variables: mid-cycle operating margin (whether the FY2025 step-up reverts to FY2022–23's 7–8% band or to FY2024's 5.9% trough) and capital-return policy (whether the cash pile stays static or starts to drain). The reinvestment runway is real but bounded — Yadea has ~5 years of overseas plant build to fund, but China capex intensity is already low. The lever for outsized compounding is on the capital-return side, not the reinvestment side; that is the unusual feature of this thesis.

4. Durability and Moat Tests

A 5-to-10-year position requires the moat to survive things the FY2025 print did not test. Four tests carry most of the weight — one each on the competitive, regulatory, technology, and financial axes. Each has a current-evidence reading, a multi-year validation signal, and a refutation signal.

The competitive test (Yadea vs AIMA on operating margin) is the cleanest binary — it can be checked from publicly-reported interim and annual results. The financial test (cash conversion ex-bills-payable) is the one the forensic page flagged: the FY2025 print is forensically supportable but the working-capital composition matters more than the headline. If both of those go Yadea's way over FY2026-28, the thesis upgrades from "narrow moat surviving" to "narrow moat widening." If either reverts, the moat call holds but the multi-year upside compresses to the dividend yield. The regulatory test is necessary but is shared with AIMA — it lifts both companies, not just Yadea.

5. Management and Capital Allocation Over a Cycle

The Dong/Qian founder pair has run this business for 25 years and through the public-market history since 2016, so the capital-allocation track record is observable rather than inferred. The pattern is consistent and gets stronger with cash generation: pay a dividend, fund a moderate capex cycle, do small bolt-on M&A, do not lever, do not chase fads, do not abuse minorities. There is no transformational M&A, no leveraged growth, no dilutive issuance, and no related-party self-dealing of consequence. Within the universe of founder-controlled HKEX-listed Chinese consumer companies, this is on the better side of the ledger — but the structural ceiling on the thesis is that 63% control means minority shareholders have no practical lever to force a capital-return regime change.

Two facts about management deserve emphasis for a multi-year view. First, the FY2024 dividend was protected through the trough — that is the kind of behavior that distinguishes a steward from an operator, and it is the evidence base for trusting the FY2025 +45% dividend hike as a regime signal rather than a one-off. Second, the FY2025 buyback of ¥49M against a market cap of ¥30B and an EV/EBITDA of ~3× is the single clearest sign of capital-allocation conservatism: if the family genuinely viewed the operating business as cheap, the buyback would be an order of magnitude larger. The PwC-to-Deloitte auditor swap (56 days after AGM reappointment) is the single open question that limits how much credibility a multi-year thesis can extend to management; a clean Deloitte FY2026 audit is the necessary precondition for any thesis upgrade.

6. Failure Modes

Three failure modes are real and observable, two are tail risks that warrant specific monitoring, and one is the catch-all "what if I am wrong" backstop. Each maps to early-warning indicators that would surface before the thesis breaks in the equity.

The single most consequential failure mode is #1 — permanent cash discount. It is the failure mode where the operating business does fine (revenue compounds at 7-10%, ROE stays in the 20-25% band) but the equity does not compound because the multiple gap to AIMA never closes. The bear case from short-interest desks is a layered version of #2 (cash flow quality) plus #6 (governance shock). The thesis breaker that is hardest to anticipate is #5 (premium-tech entrant) because Ninebot's H1 2025 growth was already abnormal and the trade-press narrative shift from Yadea-as-leader to Yadea-as-defender is a real market signal.

7. What To Watch Over Years, Not Just Quarters

Five multi-year milestones carry most of the long-term-thesis decision weight. Each is observable from public disclosures, each has a defined time horizon, and each has a defined validation/refutation pair. These are not catalysts in the trade-the-print sense; these are the milestones that move the underwriting case.